Sector News

GE to sell its biopharma business to Danaher for $21.4B

February 26, 2019
Life sciences

General Electric has moved to sell its growing biopharma manufacturing business to Danaher in a $21.4 billion deal, as the conglomerate looks to slim down its operations and pay off its lingering debt.

The trade represents an early milestone in GE’s strategy to refocus its various businesses under its newly installed chairman and CEO, Larry Culp, who took the reins last September—and who once served as Danaher’s CEO himself, from 2001 to 2014.

Danaher plans to carve out GE’s biopharma activities and operate them as a standalone business. This includes instruments and services used in biologics R&D and manufacturing, as well as the development of cell and gene therapies, such as modular therapy production lines, chromatography hardware, cell culture media and software programs.

The unit is expected to bring in about $3.2 billion in 2019 sales, with about three-quarters considered recurring revenue partly linked to its consumable products and single-use technologies. The two companies aim to close the deal in the fourth quarter of this year, with Danaher hoping to see about $100 million in cost synergies over the three years to follow.

The acquisition would also provide an “excellent complement” to Danaher’s current biologics manufacturing work, with an opportunity to provide end-to-end bioprocessing solutions to GE Biopharma’s customers, President and CEO Thomas Joyce said in a statement.

“We expect GE Biopharma to advance our growth and innovation strategy in an important and highly attractive life science market,” Joyce said, with the new purchase slotting in next to the company’s Pall, Beckman Coulter, Leica Microsystems and Sciex businesses.

GE, meanwhile, will hold on to the rest of its $17 billion healthcare business—for the time being.

“We are retaining full flexibility for growth and strategic optionality with one of the world’s leading healthcare companies, and we are pleased that our BioPharma colleagues will join a strong, established team at Danaher,” Culp said in a statement. “A more focused portfolio is the right structure for GE, and we have many options for maximizing shareholder value along the way.”

Pharmaceutical diagnostics, for example—including radiology contrast media and molecular imaging consumables—will stay within the company, linked to GE Healthcare’s stanchion medical imaging business.

GE had once planned to spin off its healthcare unit as a whole, into a 52,000-employee company with a potential enterprise value topping $70 billion. Last December it was reported that GE had filed a confidential IPO set for early 2019—but that’s now unlikely to happen following the new deal with Danaher, Culp told CNBC.

GE’s shares rose about 10% in premarket trading on the news to over $11, while Danaher’s grew at least 7.5% to over $121.

By Conor Hale

Source: Fierce Biotech

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend